ArticleFrontiers in pharmacology2026
GuiLingJi ameliorates mild cognitive impairment by targeting unsaturated fatty acid metabolism to inhibit GPR120/NF-κB mediated neuroinflammation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mild cognitive impairment (MCI) is an intermediate condition between normal aging and dementia. Drug intervention is an important way to prevent MCI from developing into dementia. GuiLingJi (GLJ) is a traditional Chinese medicine formulae and it has the effect of enhancing memory. In view of the absence of special effective drugs for MCI, GLJ warrants investigation as a potential therapeutic agent. Methods: This study uses a rat model of MCI, induced by D-galactose injections and a semi-high-fat diet, to explore the therapeutic efficacy of GLJ in MCI and elucidate the potential underlying pharmacological mechanisms by behavioral experiments and biochemical indexes, combined with serum and hippocampal metabolomics. Results: GLJ treatment mitigated D-galactose combined with semi-high-fat diet induced impairments, including abnormal blood lipids, oxidative stress, inflammation, cholinergic dysfunction, apoptosis, and reduced brain-derived neurotrophic factors, along with hippocampal damage. LC-MS metabolomics indicated that these effects involved unsaturated fatty acid and amino acid metabolism. By normalizing linoleic acid and α-linolenic acid levels and activating GPR120, GLJ inhibited the NF-κB/TNF-α pathway. Conclusion: These findings demonstrate that GLJ alleviates MCI symptoms, at least in part, by modulating fatty acid metabolism and suppressing neuroinflammation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.